The plenary presentation strengthens the clinical case for REYOBIQ in leptomeningeal metastases, a condition with no FDA-approved therapies. Monitor for updates on the ongoing multiple dose trial and any partnership or licensing discussions. The stock has historically shown large moves on clinical news, so position sizing should account for binary risk.
Price Chart
Executive Summary
Plus Therapeutics presented a plenary session at the 2026 AANS Annual Meeting highlighting Phase 1 ReSPECT-LM data for REYOBIQ in leptomeningeal metastases. Key data showed median overall survival of ~9 months at the recommended Phase 2 dose versus historical 2–6 months, high tumor cell reduction rates, and a favorable safety profile. The presentation is a positive clinical milestone but does not change the company's near-term financial outlook or regulatory path.
Key Facts
- Phase 1 ReSPECT-LM data presented at AANS plenary session showed median overall survival of ~9 months at recommended Phase 2 dose vs. historical 2–6 months
- High rates of circulating tumor cell reduction and clinical benefit observed across evaluable patients
- Target-to-off-target absorbed dose ratio exceeded 100:1, minimizing healthy tissue exposure
- Translational analyses suggest REYOBIQ may induce immune remodeling, supporting potential combination with immunotherapies
- Multiple dose Phase 1 ReSPECT-LM trial is currently enrolling patients at UT Health San Antonio
- ReSPECT-LM is funded by a $17.6M CPRIT grant; ReSPECT-PBC by a $3M DoD grant
Financial Impact
No new financial data disclosed; clinical milestone with potential to support future regulatory filings and partnership value
Risk Factors
- Clinical trial results may not replicate in larger studies
- Company has limited cash runway and may need to raise capital
- No FDA-approved therapies exist for LM, but regulatory path is uncertain
- Stock is highly volatile with low market cap ($41M)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291010 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 21, 2026 14w ago | Press Release | $3.92 | awaiting T+20 | — | — |
Jun 30, 2026 17w ago | Press Release | $4.37 $3.73 | ▼ −14.65% | ▼ −13.62% | — |
Jun 8, 2026 20w ago | EFFECT | $5.53 $4.05 | ▲ +26.76% | ▲ +28.39% | — |
Jun 5, 2026 20w ago | S-3/A | $5.41 $4.05 | ▼ −25.14% | ▼ −27.00% | — |
May 19, 2026 23w ago | Press Release | $5.83 $4.31 | ▼ −26.07% | ▼ −27.06% | — |
May 15, 2026 23w ago | Press Release | $5.84 $4.57 | ▲ +21.75% | ▲ +23.33% | — |
May 8, 2026 24w ago | Press Release | $6.12 $5.41 | ▼ −11.60% | ▼ −11.62% | — |
Apr 28, 2026 26w ago | Press Release | $5.95 $6.60 | ▲ +10.92% | ▲ +5.46% | — |
Apr 21, 2026 27w ago | 8-K | $7.14 $5.84 | ▼ −18.21% | ▼ −23.12% | — |
Apr 9, 2026 28w ago | 8-K | $3.92 $6.00 | ▲ +53.06% | ▲ +45.49% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers